find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Lymphoma
N/A
Enrolling
nct/study# NCT06067347 / PETAL
Integration of machine learning and genomics to predict outcomes for newly diagnosed, relapsed and refractory mature T-cell and NK-cell neoplasms: a global study of the PETAL Consortium
Learn More
Lymphoma
N/A
Enrolling
nct/study# NCT06323447 / PC002
Pivotal Study to Validate the Usability, Safety and Diagnostic Performance of a Novel System to Non-Invasively Detect Severe Neutropenia
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / PBL-RETROSPECTIVE
Plasmablastic Lymphoma: Changing Outcomes in People Living With and Without HIV and Other Immunosuppressed States in the Era of Modern Antiretroviral Therapy.
Learn More
Lymphoma
Phase I
Enrolling
nct/study# NCT05079282 / ONO-4685-03
Ph1 T-cell lymphoma study: An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
Learn More
Lymphoma
Phase II
Enrolling
nct/study# NCT04947319 / ONO-4059-09
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Learn More
Lymphoma
Phase I
Enrolling
nct/study# NCT05967416 / SIRP01-1001
Phase 1, Open-Label Study of Autologous SIRPA-low Macrophages (SIRPant-M) a cellular therapeutic product Administered by Intratumoral Injection Alone or in Combination with Focal External-Beam Radiotherapy in Participants with Relapsed or Refractory Non-Hodgkin’s Lymphoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.